EN DE
Watch Ardelyx Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ardelyx Inc (ARDX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Ardelyx Inc stock $2.52, price $3.01, that is 16.3% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AI Ardelyx Inc logo Thin data Nov 10, 2026

Ardelyx Inc

ARDX · US
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Revenue last quarter +16% vs. a year ago.
Expensive Growth (revenue 5y +121.9 %/yr in USD)
Moderate debt
Mixed vs. peers (5/10)
Insiders sold $2.2M (6M)
Fair value $2.52 · Overvalued
Quality 32/100
Loss-making · -11.9% net margin (TTM)
Negative free cash flow
Narrow moat 23/100
Thin data
Estimate
Watch Ardelyx Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$9.74 $0.5100 Fair Value $2.52 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.5100 – $9.74 · fair‑value band $1.89 – $3.15 · the $3.01 price screens above the $2.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Ardelyx in your weekly email

Every Wednesday you see whether Ardelyx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Show moreShow less

The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.

Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Stock analysis

Ardelyx Inc (ARDX) currently trades at $3.01, while our estimate is $2.52, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.89 (bear) to $3.15 (bull), the price of $3.01 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ardelyx Inc reported revenue of $407M in FY2025 versus $10.1M in FY2021, a compound +152.0%/yr. Reported net income was −$61.6M in FY2025.

Key figures

Market cap $747M Small · P/S ratio 1.61 · EPS (TTM) $−0.2300 · Net margin −11.9% · Return on equity −34.9% · Return on assets (EBIT) −34.5% (5-year average) · Operating margin 3.2% · Revenue (TTM) $468M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, ARDX screens richer than that median.

Fair Value

Bear $1.89 Fair Value $2.52 Bull $3.15
Price $3.01 · Downside -16.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 32
How much profit the company makes from its sales and capital
Quality Growth 61
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 30
Debt, balance sheet and risk of trouble
Investment 35
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 45
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 8 officers or directors sold shares worth $2.2M and none bought.

  • SaleJohn E BishopOfficer3× since Feb 20, 2026: 25,235 shares, avg. $4.33$109,292Aug 21, 2026
  • SaleMichael RaabPresident & CEO, Director10× since Nov 21, 2025: 456,191 shares, avg. $5.64$2.6MAug 21, 2026
  • SaleLaura A WilliamsChief Patient Officer6× since Nov 21, 2025: 164,228 shares, avg. $6.14$1.0MAug 21, 2026
  • SaleMike KelliherChief Business Officer4× since Nov 21, 2025: 30,161 shares, avg. $5.38$162,330Aug 21, 2026
  • SaleEric Duane FosterChief Commercial Officer4× since Nov 21, 2025: 32,813 shares, avg. $5.38$176,481Aug 21, 2026
  • SaleJoseph James ReillyOfficer4× since Nov 21, 2025: 23,778 shares, avg. $5.44$129,306Aug 21, 2026
  • SaleJames Parker BradyChief Human Resources Officer3× since Feb 20, 2026: 19,525 shares, avg. $4.35$84,877Aug 21, 2026
  • SaleSusan HohenleitnerChief Financial Officer3× since Feb 20, 2026: 5,046 shares, avg. $5.36$27,031Aug 21, 2026
  • BuyDavid M MottDirector333,333 shares at $5.84$1.9MFeb 20, 2026
  • SaleElizabeth A GrammerOfficer5,995 shares at $5.54$33,212Nov 21, 2025

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+98.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+121.9%
Start year 2020 (pandemic). Over 10 years: +32.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,199.0% (2020) → −10.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ARDX screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Ardelyx Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −16.3% · Above median
Profitability
Return on assets −12.3% · Above median
Net margin (12 months) −11.9% · Below median
Operating margin (12 months) 3.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 15.7% · Above median
Balance sheet
Debt / equity 1.22× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.47× · Pricier than median
P/S (12 months) 1.60× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 0
FUTURE (revenue growth)79 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)39 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ARDX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ARDX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ARDX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ARDX
argenx SE ARGX $971.55 $908.40 −7% vs ARDX
CSL Limited CSL A$201.68 A$181.40 −10% vs ARDX
Moderna, Inc MRNA $250.83 $158.70 −37% vs ARDX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ARDX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ARDX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ARDX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ardelyx Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ardelyx Inc Fair Value". https://www.fairvalue-calculator.com/stock/ARDX

Frequently asked questions

Is Ardelyx Inc (ARDX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $2.52 versus a price of $3.01, about 16% lower (overvalued).
What is the fair value of ARDX?
Our estimate for Ardelyx Inc is $2.52 (as of Nov 10, 2026), built from audited fundamentals. The current price: $3.01.
What is the quality score of ARDX?
Ardelyx Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ardelyx Inc (ARDX)?
Our calculated price target is the estimate of $2.52 (as of Nov 10, 2026). Cautious scenario $1.89, optimistic scenario $3.15. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ardelyx Inc stock forecast for 2026?
Our estimate puts fair value at $2.52, about 16% lower versus a price of $3.01 (overvalued). Cautious scenario $1.89, optimistic scenario $3.15. The calculation is refreshed regularly with new filings.
What is the revenue of Ardelyx Inc (ARDX)?
Ardelyx Inc reported trailing-twelve-month revenue of about $468M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ardelyx Inc (ARDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ardelyx Inc it is $2.52 per share (as of Nov 10, 2026), against a price of $3.01.
Is Ardelyx Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ARDX trades above its calculated fair value: price $3.01, fair value $2.52, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ARDX?
No. The price is what the market pays today ($3.01); the fair value is what the company's own numbers justify ($2.52). For Ardelyx Inc the two are $0.4900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ardelyx Inc worth?
The market values Ardelyx Inc at about $747M (market capitalisation, as of Nov 10, 2026). Per share that is $3.01; our models calculate a fair value of $2.52 per share.
What do the bullish and bearish scenarios say about ARDX?
Our models span a range for Ardelyx Inc: cautious scenario $1.89, base $2.52, optimistic $3.15 per share (as of Nov 10, 2026, price $3.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ardelyx Inc (ARDX)?
Balance-sheet figures for Ardelyx Inc (as of Nov 10, 2026): return on equity −34.9%, debt of 1.22 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ARDX from its 52-week high?
Ardelyx Inc trades at $3.01, about 62% below its 52-week high of $7.99 and 5% above the low of $2.88 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.52 is for.
Which stocks are comparable to Ardelyx Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ardelyx Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $3.01, calculated fair value $2.52 (−16%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ardelyx Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ardelyx Inc (ARDX)?
The closing price on Nov 10, 2026 was $3.01. Our estimate is $2.52, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ardelyx Inc right now?
Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ardelyx Inc

How large is the market capitalisation of Ardelyx Inc (ARDX)?
The market capitalisation of Ardelyx Inc is $747M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ardelyx Inc (ARDX)?
The price-to-sales ratio of Ardelyx Inc is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ardelyx Inc (ARDX)?
Earnings per share at Ardelyx Inc are $−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ardelyx Inc (ARDX)?
The net margin of Ardelyx Inc is −11.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ardelyx Inc (ARDX)?
The return on equity (ROE) of Ardelyx Inc is −34.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ardelyx Inc (ARDX)?
On an EBIT basis the return on assets of Ardelyx Inc is −34.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ardelyx Inc (ARDX)?
The operating margin of Ardelyx Inc is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ardelyx Inc (ARDX)?
Revenue at Ardelyx Inc is growing +15.7% versus a year earlier (3y avg +98.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ardelyx Inc (ARDX) generate?
The free cash flow of Ardelyx Inc is −$44.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ardelyx Inc (ARDX) carry?
The net debt of Ardelyx Inc is $144M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ardelyx Inc in the live analysis

One click puts Ardelyx Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.